July 27, 2021

Pfizer and BioNTech’s Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) are right on the heels of Moderna (NASDAQ: MRNA) in the race to potentially develop a messenger RNA (mRNA) vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. In an interview with The Wall Street Journal, BioNTech CEO Ugur Sahin predicted the companies will have enough data for a vaccine to be ready for approval by December. The companies are still trying to figure out which of multiple vaccine candidates should be taken into a 30,000-patient phase 2/3 clinical trial that is scheduled to start this month.

Leave a Reply

Your email address will not be published. Required fields are marked *